Not Yet RecruitingPhase 4ketamine

Ketamine for the Treatment of Refractory Status Epilepticus

Sponsored by Thomas Jefferson University

NCT ID
NCT07177235
Target Enrollment
50 participants
Start Date
2025-11
Est. Completion
2028-07

About This Study

This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).

Conditions Studied

Refractory Status Epilepticus

Interventions

  • Ketamine
  • Midazolam

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

1. Adults 18 years of age or older
2. Patients with refractory status epilepticus unresponsive to appropriately dosed first line agents administered intravenous or intraosseous and one second line agent

   1. First line agents: lorazepam, midazolam, or diazepam
   2. Second line agents: phenytoin (20 mg/kg), valproate (40 mg/kg), levetiracetam (60 mg/kg), lacosamide (400 mg)
3. All etiologies of status epilepticus will be included

Exclusion Criteria:

1. Exclusively psychogenic non epileptic seizures
2. Pregnant individuals
3. Incarcerated individuals
4. Patients with hypersensitivity to ketamine or any component of the formulation
5. Conditions in which an increase in blood pressure would be hazardous
6. Focal motor status epilepticus
7. Status epilepticus lasting \> 24 hours prior to enrollment (SRSE)
8. Patients with EEG in the ictal-interictal continuum (IIC)

Study Locations (1)

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Syed 0 Shah, MD
CONTACT
Syed.Shah@Jefferson.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source